Jonathan C. Cheng

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

J. Lunceford, Chunsheng Zhang, T. Mcclanahan, 2018, Science.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012

Jonathan C. Cheng, T. Seiwert, R. Mehra, 2018, British Journal of Cancer.

Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study

K. Harrington, Jonathan C. Cheng, L. Siu, 2020, Clinical Cancer Research.

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.

V. Grégoire, J. Machiels, K. Harrington, 2020, Future oncology.

Radiation Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens.

Jonathan C. Cheng, An Liu, T. Schultheiss, 2019, International journal of radiation oncology, biology, physics.

Impact of drug therapy, radiation dose, and dose rate on renal toxicity following bone marrow transplantation.

Jonathan C. Cheng, T. Schultheiss, J. Wong, 2008, International journal of radiation oncology, biology, physics.

Biomarkers predictive of response to pembrolizumab in head and neck cancer

J. Lunceford, M. Ayers, R. Cristescu, 2022, Cancer medicine.